2 recruiting, 1 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Code Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV Gammora® - HIV Seropositivity | Phase 2 | Active not recruiting | Federal University of São Paulo | 40 | 2025-01-01 | 2026-06-01 |
| Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants ICF, Eligibility Assessment, Demographic data - HIV, HIV Infection | Phase 2 | Recruiting | Code Pharma | 40 | 2023-07-20 | 2024-11-06 |
| Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19 Covidir injections, Quantitative PCR SARS-CoV-2, IgM and IgG dosage - COVID-19 | Phase 2 | Recruiting | Code Pharma | 130 | 2022-01-20 | 2024-10-02 |
| Study of Codivir in Patients With COVID-19 Covidir injections, One Step Test, IgM and IgG dosage - Covid19 | Phase 1 | Completed | Code Pharma | 12 | 2021-03-29 | 2021-11-02 |
COVID-19 (2) · Acquired Immunodeficiency Syndrome (1) · Coronavirus Infections (1) · HIV Infections (1) · HIV Seropositivity (1)
Electrocardiography (2) · Anti-Retroviral Agents (1) · Body Height (1) · Body Mass Index (1) · COVID-19 Nucleic Acid Testing (1) · Darunavir (1) · Demography (1) · Hematologic Tests (1) · Physical Examination (1) · Pregnancy Tests (1) · Random Allocation (1) · Restraint, Physical (1) · Ritonavir (1) · Tenofovir (1)
Brazil (4)